Gilead Sciences (GILD) Rating Lowered to C at TheStreet

Gilead Sciences (NASDAQ:GILD) was downgraded by investment analysts at TheStreet from a “b-” rating to a “c” rating in a note issued to investors on Tuesday.

A number of other brokerages have also weighed in on GILD. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 target price for the company. in a research report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and decreased their target price for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Bank of America boosted their price target on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday. Morgan Stanley reduced their price target on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Barclays reissued an “overweight” rating and issued a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $85.84.

Shares of Gilead Sciences (NASDAQ:GILD) traded down $0.78 during midday trading on Tuesday, reaching $81.98. The company’s stock had a trading volume of 1,910,064 shares, compared to its average volume of 9,584,469. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market cap of $108,080.00, a price-to-earnings ratio of 9.33, a PEG ratio of -1.77 and a beta of 1.22. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 48.88% and a net margin of 17.73%. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 EPS. equities research analysts anticipate that Gilead Sciences will post 6.47 earnings per share for the current year.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares in the company, valued at approximately $5,298,544.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 578,333 shares of company stock worth $44,100,508 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of GILD. Capital International Investors grew its stake in Gilead Sciences by 86.6% during the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after purchasing an additional 5,205,983 shares during the last quarter. Sanders Capital LLC boosted its stake in shares of Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after buying an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after buying an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. boosted its stake in shares of Gilead Sciences by 5,461.1% in the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock worth $237,675,000 after buying an additional 3,257,969 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after buying an additional 2,700,600 shares during the last quarter. Institutional investors and hedge funds own 75.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences (GILD) Rating Lowered to C at TheStreet” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/02/08/gilead-sciences-gild-rating-lowered-to-c-at-thestreet.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply